Last reviewed · How we verify

Tramadol PR oral — Competitive Intelligence Brief

Tramadol PR oral (Tramadol PR oral) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic with monoamine reuptake inhibition. Area: Pain Management.

phase 3 Opioid analgesic with monoamine reuptake inhibition Mu opioid receptor; norepinephrine transporter; serotonin transporter Pain Management Biologic Live · refreshed every 30 min

Target snapshot

Tramadol PR oral (Tramadol PR oral) — Pfizer. Tramadol is a synthetic opioid analgesic that binds to mu opioid receptors and also inhibits the reuptake of norepinephrine and serotonin to provide pain relief.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tramadol PR oral TARGET Tramadol PR oral Pfizer phase 3 Opioid analgesic with monoamine reuptake inhibition Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol HCl Tramadol HCl Labopharm Inc. marketed Synthetic opioid analgesic with monoamine reuptake inhibition Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol /acetaminophen Tramadol /acetaminophen Johnson & Johnson Taiwan Ltd marketed Opioid analgesic combination Mu opioid receptor; norepinephrine transporter; serotonin transporter; cyclooxygenase
Tramadol IV (Tradonal® IV) Tramadol IV (Tradonal® IV) University Hospital, Ghent marketed Opioid analgesic with monoamine reuptake inhibition Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramal® Tramal® Apsen Farmaceutica S.A. marketed Synthetic opioid analgesic Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol OAD Tramadol OAD Labopharm Inc. phase 3 Opioid analgesic with norepinephrine-serotonin reuptake inhibition Mu opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol 50 Tramadol 50 Grünenthal GmbH phase 3 Synthetic opioid analgesic Mu opioid receptor; norepinephrine transporter; serotonin transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic with monoamine reuptake inhibition class)

  1. Al-Azhar University · 1 drug in this class
  2. Pfizer · 1 drug in this class
  3. University Hospital, Ghent · 1 drug in this class
  4. University of Southern Denmark · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tramadol PR oral — Competitive Intelligence Brief. https://druglandscape.com/ci/tramadol-pr-oral. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: